Unity Net Income From Continuing Ops from 2010 to 2024

UBX Stock  USD 1.14  0.02  1.72%   
Unity Biotechnology Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -55.2 M in 2024. During the period from 2010 to 2024, Unity Biotechnology Net Loss regression line of annual values had significance of  0.01 and arithmetic mean of (49,230,037). View All Fundamentals
 
Net Loss  
First Reported
2016-12-31
Previous Quarter
-5.3 M
Current Value
-6.5 M
Quarterly Volatility
10.4 M
 
Covid
Check Unity Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unity Biotechnology's main balance sheet or income statement drivers, such as Interest Income of 3.3 M, Depreciation And Amortization of 1.5 M or Interest Expense of 1.9 M, as well as many indicators such as Price To Sales Ratio of 104, Dividend Yield of 0.0 or PTB Ratio of 1.07. Unity financial statements analysis is a perfect complement when working with Unity Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Unity Biotechnology Correlation against competitors.
For more information on how to buy Unity Stock please use our How to Invest in Unity Biotechnology guide.

Latest Unity Biotechnology's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Unity Biotechnology over the last few years. It is Unity Biotechnology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unity Biotechnology's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Unity Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(49,230,037)
Coefficient Of Variation(44.15)
Mean Deviation18,180,839
Median(44,656,000)
Standard Deviation21,733,661
Sample Variance472.4T
Range63.4M
R-Value(0.67)
Mean Square Error278.3T
R-Squared0.45
Significance0.01
Slope(3,270,824)
Total Sum of Squares6612.9T

Unity Net Income From Continuing Ops History

2024-55.2 M
2023-52.5 M
2022-60.1 M
2021-60.7 M
2020-93.8 M
2019-82.2 M
2018-76.4 M

About Unity Biotechnology Financial Statements

Unity Biotechnology investors use historical fundamental indicators, such as Unity Biotechnology's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unity Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-52.5 M-55.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Unity Stock Analysis

When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.